The sale marks the first insider transaction by the biotech firm’s CFO in over a year amid recent stock volatility.
Travere Therapeutics CFO Jennifer Cline sold $115,368 worth of company stock, according to regulatory filings. The transaction involved 5,000 shares at an average price of $23.07 per share, executed on August 12.
The sale follows a period of heightened volatility for Travere’s stock, which has fluctuated between $18 and $28 over the past three months. Prior to this, Cline’s last reported transaction was a purchase of 2,000 shares in June 2023 at $12.50 per share.
Shares of Travere (TVTX) showed minimal reaction in after-hours trading, holding steady near $23.10.